Functional Mechanism of MicroRNA-25-3p in Hilar Cholangiocarcinoma Cell Proliferation and Migration Through Regulation of Dual Specificity Phosphatase 5

References

• Soares KC, Jarnagin WR. The landmark series: hilar cholangiocarcinoma. Ann Surg Oncol. 2021;28(8):1–9. doi:10.1245/s10434-021-09871-6.
   Web of Science ®Google Scholar
• Zaydfudim VM, Rosen CB, Nagorney DM. Hilar cholangiocarcinoma. Surg Oncol Clin N Am. 2014;23(2):247–263. doi:10.1016/j.soc.2013.10.005.
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. doi:10.1038/s41575-020-0310-z.
   PubMed Web of Science ®Google Scholar
• Anderson B, Doyle MBM. Surgical considerations of hilar cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28(4):601–617. doi:10.1016/j.soc.2019.06.003.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Ivanics T, Subramanian V, Doyle M, Heimbach JK, Hong JC. Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles. Int J Surg. 2020;82S:77–81. doi:10.1016/j.ijsu.2020.04.067.
   PubMedGoogle Scholar
• Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3(1):18–34. doi:10.3978/j.issn.2304-3881.2014.02.05.
   PubMedGoogle Scholar
• Inchingolo R, Acquafredda F, Ferraro V, et al. Non-surgical treatment of hilar cholangiocarcinoma. World J Gastrointest Oncol. 2021;13(11):1696–1708. doi:10.4251/wjgo.v13.i11.1696.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, KhorramKhorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465. doi:10.1002/jcp.27486.
   PubMed Web of Science ®Google Scholar
• Burroughs AM, Ando Y. Identifying and characterizing functional 3’ nucleotide addition in the miRNA pathway. Methods. 2019;152:23–30. doi:10.1016/j.ymeth.2018.08.006.
   PubMed Web of Science ®Google Scholar
• Puik JR, Meijer LL, Le Large TY, et al. miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. Pharmacogenomics. 2017;18(14):1343–1358. doi:10.2217/pgs-2017-0010.
   PubMed Web of Science ®Google Scholar
• Zhang J, Bai R, Li M, et al. Excessive miR-25-3p maturation via N(6)-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 2019;10(1):1858. doi:10.1038/s41467-019-09712-x.
   PubMedGoogle Scholar
• Ning L, Zhang M, Zhu Q, Hao F, Shen W, Chen D. miR-25-3p inhibition impairs tumorigenesis and invasion in gastric cancer cells in vitro and in vivo. Bioengineered. 2020;11(1):81–90. doi:10.1080/21655979.2019.1710924.
   PubMed Web of Science ®Google Scholar
• Shi T, Morishita A, Kobara H, Masaki T. The role of microRNAs in cholangiocarcinoma. IJMS. 2021;22(14):7627. doi:10.3390/ijms22147627.
   Google Scholar
• Patterson KI, Brummer T, O’Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009;418(3):475–489. doi:10.1042/bj20082234.
   PubMedGoogle Scholar
• Zhang H, Zheng H, Mu W, et al. DUSP16 ablation arrests the cell cycle and induces cellular senescence. FEBS J. 2015;282(23):4580–4594. doi:10.1111/febs.13518.
   PubMed Web of Science ®Google Scholar
• Cai C, Chen JY, Han ZD, et al. Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer. Int J Clin Exp Med. 2015;8(3):4186–4194. doi:.
   PubMed Web of Science ®Google Scholar
• Ding J, Li J, Wang H, et al. Long noncoding RNA CRNDE promotes colorectal cancer cell proliferation via epigenetically silencing DUSP5/CDKN1A expression. Cell Death Dis. 2017;8(8):e2997. doi:10.1038/cddis.2017.328.
   PubMed Web of Science ®Google Scholar
• Wang L, Hu J, Qiu D, et al. Dual-specificity phosphatase 5 suppresses ovarian cancer progression by inhibiting IL-33 signaling. Am J Transl Res. 2019;11(2):844–854. doi:.
   PubMed Web of Science ®Google Scholar
• Bornigen D, Tyekucheva S, Wang X, et al. Computational reconstruction of NFkappaB pathway interaction mechanisms during prostate cancer. PLoS Comput Biol. 2016;12(4):e1004820. doi:10.1371/journal.pcbi.1004820.
   PubMed Web of Science ®Google Scholar
• Nokin MJ, Bellier J, Durieux F, et al. Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. Breast Cancer Res. 2019;21(1):11. doi:10.1186/s13058-018-1095-7.
   PubMedGoogle Scholar
• Du M, Zhuang Y, Tan P, Yu Z, Zhang X, Wang A. microRNA-95 knockdown inhibits epithelial-mesenchymal transition and cancer stem cell phenotype in gastric cancer cells through MAPK pathway by upregulating DUSP5. J Cell Physiol. 2020;235(2):944–956. doi:10.1002/jcp.29010.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zheng J, Ye Y, Zhao K, Wang R, Wang R. MicroRNA253p regulates human nucleus pulposus cell proliferation and apoptosis in intervertebral disc degeneration by targeting Bim. Mol Med Rep. 2020;22(5):3621–3628. doi:10.3892/mmr.2020.11483.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu H. Klatskin tumor: a population-based study of incidence and survival. Med Sci Monit. 2019;25:4503–4512. doi:10.12659/MSM.914987.
   PubMed Web of Science ®Google Scholar
• Rios P, Nunes-Xavier CE, Tabernero L, Kohn M, Pulido R. Dual-specificity phosphatases as molecular targets for inhibition in human disease. Antioxid Redox Signal. 2014;20(14):2251–2273. doi:10.1089/ars.2013.5709.
   PubMed Web of Science ®Google Scholar
• Ueda K, Arakawa H, Nakamura Y. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene. 2003;22(36):5586–5591. doi:10.1038/sj.onc.1206845.
   PubMed Web of Science ®Google Scholar
• Staege MS, Muller K, Kewitz S, et al. Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells. PLoS One. 2014;9(2):e89577. doi:10.1371/journal.pone.0089577.
   PubMed Web of Science ®Google Scholar
• Gruszka R, Zakrzewska M. The oncogenic relevance of miR-17-92 cluster and its paralogous miR-106b-25 and miR-106a-363 clusters in brain tumors. IJMS. 2018;19(3):879. doi:10.3390/ijms19030879.
   Google Scholar
• Altan Z, Sahin Y. miR-203 suppresses pancreatic cancer cell proliferation and migration by modulating DUSP5 expression. Mol Cell Probes. 2022;66:101866. doi:10.1016/j.mcp.2022.101866.
   PubMed Web of Science ®Google Scholar
• Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74–88. doi:10.1038/s41580-021-00404-3.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 2009;16(2):36–43. doi:10.3747/co.v16i2.428.
   PubMed Web of Science ®Google Scholar
• Paternot S, Colleoni B, Bisteau X, Roger PP. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes. Cell Cycle. 2014;13(18):2879–2888. doi:10.4161/15384101.2014.946841.
   PubMed Web of Science ®Google Scholar
• Dong P, Zhang C, Parker BT, You L, Mathey-Prevot B. Cyclin D/CDK4/6 activity controls G1 length in mammalian cells. PLoS One. 2018;13(1):e0185637. doi:10.1371/journal.pone.0185637.
   PubMed Web of Science ®Google Scholar
• Zhan J, Tong J, Fu Q. Long non‑coding RNA LINC00858 promotes TP53‑wild‑type colorectal cancer progression by regulating the microRNA‑25‑3p/SMAD7 axis. Oncol Rep. 2020;43(4):1267–1277. doi:10.3892/or.2020.7506.
   PubMed Web of Science ®Google Scholar
• Zare-Chahoki A, Ahmadi-Zeidabadi M, Azadarmaki S, Ghorbani S, Noorbakhsh F. Inflammation in an animal model of multiple sclerosis leads to microRNA-25-3p dysregulation associated with inhibition of Pten and Klf4. Iran J Allergy Asthma Immunol. 2021;20(3):314–325. doi:10.18502/ijaai.v20i3.6337.
   PubMed Web of Science ®Google Scholar
• Rao HC, Wu ZK, Wei SD, et al. MiR-25-3p serves as an oncogenic microRNA by downregulating the expression of merlin in osteosarcoma. Cancer Manag Res. 2020;12:8989–9001. doi:10.2147/CMAR.S262245.
   PubMed Web of Science ®Google Scholar
• Ma Z, Gao X, Shuai Y, et al. EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer. Cell Prolif. 2021;54(1):e12922. doi:10.1111/cpr.12922.
   PubMed Web of Science ®Google Scholar
• Wang XY, Jian X, Sun BQ, Ge XS, Huang FJ, Chen YQ. LncRNA ROR1-AS1 promotes colon cancer cell proliferation by suppressing the expression of DUSP5/CDKN1A. Eur Rev Med Pharmacol Sci. 2020;24(3):1116–1125. doi:10.26355/eurrev_202002_20162.
   PubMed Web of Science ®Google Scholar
• Shin SH, Park SY, Kang GH. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis. Am J Pathol. 2013;182(4):1275–1285. doi:10.1016/j.ajpath.2013.01.004.
   PubMed Web of Science ®Google Scholar
• Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ. PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res. 2014;12(3):322–334. doi:10.1158/1541-7786.MCR-13-0543.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tong Z, Sun Z, Zhu G, Shen E, Huang Y. MiR-25-3p targets PTEN to regulate the migration, invasion, and apoptosis of esophageal cancer cells via the PI3K/AKT pathway. Biosci Rep. 2020;40(10):BSR20201901. doi:10.1042/BSR20201901.
   Google Scholar